Gemfibrozil: Difference between revisions
imported>David E. Volk m (→External Links) |
imported>Robert Badgett No edit summary |
||
| Line 2: | Line 2: | ||
[[Image:Gemfibrozil structure.jpg|right|thumb|200px|{{#ifexist:Template:Gemfibrozil structure.jpg/credit|{{Gemfibrozil structure.jpg/credit}}<br/>|}}Gemfibrozil.]] | [[Image:Gemfibrozil structure.jpg|right|thumb|200px|{{#ifexist:Template:Gemfibrozil structure.jpg/credit|{{Gemfibrozil structure.jpg/credit}}<br/>|}}Gemfibrozil.]] | ||
'''Gemfibrozil''', or 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid), is | '''Gemfibrozil''', or 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid), is a [[Antilipemic agent|antilipemic ]] [[medication]] that lowers serum [[triglyceride]] levels, with variable effects on [[cholesterol]]. The [[VLDL]] fraction is preferentially lowered and LDL less so. The HDL subfractions HDL2 and HDL3, and [[apolipoprotein]]s A-I and A-II, are increased. Gemfibrozil is a [[fibric acid]] antilipemic drug similar to [[clofibrate]] that is used to treat [[hyperlipoproteinemia]] and supplimental therapy for type IIb [[hypercholesterolemia]]. Gemfibrozil increases lipoprotein triglyceride lipolysis by increasing the activity of extrahepatic [[lipoprotein lipase]]. Chylomicrons are degraded, VLDLs are converted to LDLs, and LDLs are converted to HDL. | ||
== Drug Interactions == | == Drug Interactions == | ||
| Line 9: | Line 9: | ||
== Brand Names == | == Brand Names == | ||
<div class= style="-moz-column-count:3; column-count:3;"> | |||
*Apo-Gemfibrozil | *Apo-Gemfibrozil | ||
*Bolutol | *Bolutol | ||
| Line 28: | Line 29: | ||
*Novo-Gemfibrozil | *Novo-Gemfibrozil | ||
*Nu-Gemfibrozil | *Nu-Gemfibrozil | ||
</div> | |||
== External Links == | == External Links == | ||
{{CZMed}} | |||
Revision as of 23:11, 21 February 2009
Gemfibrozil, or 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid), is a antilipemic medication that lowers serum triglyceride levels, with variable effects on cholesterol. The VLDL fraction is preferentially lowered and LDL less so. The HDL subfractions HDL2 and HDL3, and apolipoproteins A-I and A-II, are increased. Gemfibrozil is a fibric acid antilipemic drug similar to clofibrate that is used to treat hyperlipoproteinemia and supplimental therapy for type IIb hypercholesterolemia. Gemfibrozil increases lipoprotein triglyceride lipolysis by increasing the activity of extrahepatic lipoprotein lipase. Chylomicrons are degraded, VLDLs are converted to LDLs, and LDLs are converted to HDL.
Drug Interactions
Gemfibrozil increases the anticoagulant effects of anisindione, dicumarol, acenocoumarol and warfarin. There is an increased risk of myopathy/rhaddomyolysis when gemfibrizol is taken with the cholesterol lowering statin drugs atorvastatin (Lipitor), cerivastatin, fluvastatin (Lescol), lovastatin, pravastatin (Pravachol), and simvastatin (Vytorin). Gemfibrizol increases the effects and toxicity of pioglitazone, rosiglitazone and repaglinide. The statin rosuvastatin (Crestor) may increase the effect of gemfibrizol, and gemfibrizol decreases the effects of ursodiol.
Brand Names
- Apo-Gemfibrozil
- Bolutol
- Cholespid
- Decrelip
- Fibratol
- Fibrocit
- Gemfibril
- Gemfibromax
- Gemlipid
- Gen-Fibro
- Genlip
- Gevilon
- Hipolixan
- Jezil
- Lipozid
- Lipur
- Lopid
- Novo-Gemfibrozil
- Nu-Gemfibrozil
External Links
The most up-to-date information about Gemfibrozil and other drugs can be found at the following sites.
- Gemfibrozil - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Gemfibrozil - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Gemfibrozil - Detailed information from DrugBank.